A treat-and-extend regimen with aflibercept showed both anatomical and functional improvements for patients with nAMD and PCV during a two-year study.

In this retrospective review of medical charts, trends in systemic treatment use among psoriasis patients in Japan pointed to several notable findings.

Russell D Cohen, MD, explains how biosimilars represent an opportunity to expand access and reduce the financial burden of high-cost biologics.

A meta-analysis of trials examining use of preoperative iron infusions suggests use could reduce need for blood transfusions by 33% among patients undergoing colorectal surgery.

Retina specialists discuss treatment and adherence strategies for patients with nAMD and DME. They also comment on the future of nAMD and DME management.

Retina specialists discuss factors to consider when selecting a therapy for patients with neovascular AMD and DME as well as loading-dose recommendations for select patients.

Retina specialists comment on switching patients from 2 mg to 8 mg of aflibercept for the management of neovascular age-related macular degeneration and diabetic macular edema and transitioning a patient who has good control with aflibercept to a newer therapy.

In an interview with HCPLive, Rishi Kakar, MD, discussed how KarXT is a novel molecule unique from currently available schizophrenia treatments.

Expert dermatologists highlight the future of plaque psoriasis treatment, commenting on advances in therapy as well as increasing access to treatment.

Benjamin Lockshin, MD, FAAD; and Jennifer Soung, MD, share their experience with IL-23 inhibitors for the treatment of plaque psoriasis in clinical practice.

Benjamin Lockshin, MD, FAAD, comments on the higher efficacy and reliability of recent IL-17 and IL-23 inhibitors and how these factors into treatment selection for patients with plaque psoriasis.

November’s Gastroenterology Month in Review features an FDA approval, the discontinuation of a phase 3 clinical program, and news about Clostridioides difficile testing and risk factors.

We kick off our annual recap series with some reflections from our expert advisory board, on topics ranging from AI and cell therapies, to semaglutide and RSV vaccines.

Data from the phase 3 study confirmed the lot consistency, immunogenicity, safety, and tolerability of a toxoid-based Clostridioides difficile vaccine.

This new data adds to the growing body of literature regarding the benefits and risks of prescribing isotretinoin for dermatology patients.

At 12 weeks, significantly more patients with fibromyalgia receiving the smartphone-based intervention reported clinical improvements compared with the control group.

Metformin use was associated with a reduced likelihood of any AMD and dry AMD in a sample of patients without diabetes.

In this interview with Dr. Eichenfield, comparisons between ruxolitinib and other treatments for eczema were discussed.

Findings may be related to a variety of influences including a slower life pace during the pandemic and resilience to prolonged stressors.

Released on Nov. 30, 2023, the new AFib guidance from the ACC/AHA contains update recommendations for early and aggressive rhythm control, wearables, left atrial appendage occlusion, and more.

In a new study, decreased plasma EGR1 protein levels and patients with fibromyalgia had a statistically significant relationship.

An overview of treatment regimens for HCV.

8 weeks of treatment with glecaprevir/pibrentasvir was found to be safe and effective among patients with HCV aged 3-17 years.

Experts explore the challenges of multi-product topical treatment algorithms for seborrheic dermatitis (SD) and the value of once-a-day solutions in fostering adherence, improved quality of life, and overall better outcomes.

Expert hepatologist Mark Sulkowski, MD discusses which patients are candidates for HCV treatment.